Diagnosis & Disease Information

New Biologic Agent May Benefit Men with CRPC

CHICAGO—Tasquinimod, a novel biologic agent, may significantly slow the rate of disease progression and improve progression-free survival in patients with metastatic castrate-resistant prostate cancer (CRCP), according to a new study presented at the American Society of Clinical Oncology annual meeting.

Next post in Prostate Cancer